Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers

INTRODUCTION: At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations...

Descripción completa

Detalles Bibliográficos
Autores principales: Dam, Erik B, Loog, Marco, Christiansen, Claus, Byrjalsen, Inger, Folkesson, Jenny, Nielsen, Mads, Qazi, Arish A, Pettersen, Paola C, Garnero, Patrick, Karsdal, Morten A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745797/
https://www.ncbi.nlm.nih.gov/pubmed/19630944
http://dx.doi.org/10.1186/ar2774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745797/
https://www.ncbi.nlm.nih.gov/pubmed/19630944
http://dx.doi.org/10.1186/ar2774

Ejemplares similares